Efficacy and safety of camrelizumab plus apatinib in advanced urachal cancer (RUN-SC-0102): a single-arm, multicentre, phase 2 trial in China.

AiTan (rivoceranib) - Elevar Therapeutics

AiRuiKa (camrelizumab) - Elevar Therapeutics

http://www.ncbi.nlm.nih.gov/pubmed/42256684

Linjun Hu; Mengyang Ju; Sheng Zhang; Wangjun Yan; Wenfeng Li; Xiongjun Ye

Jun 9, 2026